{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:16:36Z","timestamp":1777482996565,"version":"3.51.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["NIHR200490"],"award-info":[{"award-number":["NIHR200490"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Health Service"},{"DOI":"10.13039\/100006662","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000276","name":"Department of Health and Social Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Health Service"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Colchicine is commonly used to prevent flares when starting urate-lowering therapy for gout. Patients with gout are frequently concurrently prescribed other medications (such as statins) that may interact with colchicine, increasing the risk of adverse events. The aim of this study was to describe potential prognostic factors for adverse events in patients prescribed colchicine when initiating allopurinol.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective cohort study in linked UK Clinical Practice Research Datalink and Hospital Episode Statistics datasets. Adults initiating allopurinol for gout with colchicine (1 April 1997 to 30 November 2016) were included. Potential prognostic factors were defined, and the likelihood of adverse events, including diarrhoea, nausea or vomiting, myocardial infarction, neuropathy, myalgia, myopathy, rhabdomyolysis and bone marrow suppression, were estimated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>From 1 April 1997 to 30 November 2016, 13\u2009945 people with gout initiated allopurinol with colchicine prophylaxis [mean age 63.9 (s.d. 14.7) years, 78.2% male]. One-quarter (26%, 95% CI 25%, 27%) were prescribed one or more potentially interacting medicines, most commonly statins (21%, 95% CI 20%, 22%). Statins were not associated with increased adverse events, although other drugs were associated with some adverse outcomes. Diarrhoea and myocardial infarction were associated with more comorbidities and more severe chronic kidney disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>People were given colchicine prophylaxis despite commonly having preexisting prescriptions for medications with potential to interact with colchicine. Adverse events were more common in people who had more comorbidities and certain potentially interacting medications. Our findings will provide much-needed information about prognostic factors for colchicine-related adverse events that can inform treatment decisions about prophylaxis when initiating allopurinol.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae229","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:13:45Z","timestamp":1713399225000},"page":"1147-1154","source":"Crossref","is-referenced-by-count":4,"title":["Prognostic factors for colchicine prophylaxis-related adverse events when initiating allopurinol for gout: retrospective cohort study"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1227-2703","authenticated-orcid":false,"given":"Ram","family":"Bajpai","sequence":"first","affiliation":[{"name":"School of Medicine, Keele University , Keele,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7362-0257","authenticated-orcid":false,"given":"Richard","family":"Partington","sequence":"additional","affiliation":[{"name":"School of Medicine, Keele University , Keele,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6645-5751","authenticated-orcid":false,"given":"Sara","family":"Muller","sequence":"additional","affiliation":[{"name":"School of Medicine, Keele University , Keele,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry","family":"Forrester","sequence":"additional","affiliation":[{"name":"School of Medicine, Keele University , Keele,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2677-1028","authenticated-orcid":false,"given":"Christian D","family":"Mallen","sequence":"additional","affiliation":[{"name":"School of Medicine, Keele University , Keele,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorna","family":"Clarson","sequence":"additional","affiliation":[{"name":"School of Medicine, Keele University , Keele,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nishita","family":"Padmanabhan","sequence":"additional","affiliation":[{"name":"School of Medicine, Keele University , Keele,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Whittle","sequence":"additional","affiliation":[{"name":"School of Medicine, Keele University , Keele,","place":["UK"]},{"name":"Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham , Birmingham,","place":["UK"]},{"name":"National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre , Birmingham,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Roddy","sequence":"additional","affiliation":[{"name":"School of Medicine, Keele University , Keele,","place":["UK"]},{"name":"Haywood Academic Rheumatology Centre, Midlands Partnership University NHS Foundation Trust , Stoke-on-Trent,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"key":"2025030500184173000_keae229-B1","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","article-title":"Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study","volume":"74","author":"Kuo","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025030500184173000_keae229-B2","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/art.40807","article-title":"Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007\u20132016","volume":"71","author":"Chen-Xu","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025030500184173000_keae229-B3","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/rheumatology\/key096","article-title":"Comorbidity clusters in people with gout: an observational cohort study with linked medical record review","volume":"57","author":"Bevis","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2025030500184173000_keae229-B4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2017.12.005","article-title":"Health-related quality of life in gout in primary care: baseline findings from a cohort study","volume":"48","author":"Chandratre","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2025030500184173000_keae229-B5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025030500184173000_keae229-B6","doi-asserted-by":"crossref","first-page":"e1\u201320","DOI":"10.1093\/rheumatology\/kex156","article-title":"The British Society for Rheumatology Guideline for the Management of Gout","volume":"56","author":"Hui","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2025030500184173000_keae229-B7","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/art.41247","article-title":"2020 American College of Rheumatology Guideline for the Management of Gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025030500184173000_keae229-B8","author":"National Institute for Health and Care Excellence","year":"2022"},{"key":"2025030500184173000_keae229-B9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/1742395310378761","article-title":"Patients and providers view gout differently: a qualitative study","volume":"6","author":"Harrold","year":"2010","journal-title":"Chronic Illn"},{"key":"2025030500184173000_keae229-B10","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1136\/ard-2023-224154","article-title":"Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout: propensity score-matched cohort studies in the UK Clinical Practice Research Datalink","volume":"82","author":"Roddy","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025030500184173000_keae229-B11","first-page":"5","article-title":"Medicines and healthcare products regulatory agency","volume":"3","year":"2009","journal-title":"Drug Safety Update"},{"key":"2025030500184173000_keae229-B12","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13075-015-0610-9","article-title":"E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies","volume":"17","author":"Roughley","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2025030500184173000_keae229-B13","doi-asserted-by":"crossref","first-page":"f5648","DOI":"10.1136\/bmj.f5648","article-title":"Gout","volume":"347","author":"Roddy","year":"2013","journal-title":"BMJ"},{"key":"2025030500184173000_keae229-B14","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/phar.2674","article-title":"A systematic review of the drug\u2013drug interaction between statins and colchicine: patient characteristics, etiologies, and clinical management strategies","volume":"42","author":"Schwier","year":"2022","journal-title":"Pharmacotherapy"},{"key":"2025030500184173000_keae229-B15","doi-asserted-by":"crossref","first-page":"152150","DOI":"10.1016\/j.semarthrit.2022.152150","article-title":"Systematic review of colchicine neuromyopathy: risk factors, duration and resolution","volume":"58","author":"McEwan","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"2025030500184173000_keae229-B16","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/ije\/dyz034","article-title":"Data resource profile: clinical Practice Research Datalink (CPRD) Aurum","volume":"48","author":"Wolf","year":"2019","journal-title":"Int J Epidemiol"},{"key":"2025030500184173000_keae229-B17","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ije\/dyv098","article-title":"Data Resource Profile: Clinical Practice Research Datalink (CPRD)","volume":"44","author":"Herrett","year":"2015","journal-title":"Int J Epidemiol"},{"key":"2025030500184173000_keae229-B18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2125.1997.00647.x","article-title":"Omeprazole, other antiulcer drugs and newly diagnosed gout","volume":"44","author":"Meier","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"2025030500184173000_keae229-B19","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1136\/ard-2022-222668","article-title":"Serum urate outcomes of treat-to-target urate lowering treatment: results of a nationwide cohort study from 1997 to the COVID-19 pandemic using data from the Clinical Practice Research Datalink","volume":"81","author":"Abhishek","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025030500184173000_keae229-B20","doi-asserted-by":"crossref","first-page":"100416","DOI":"10.1016\/j.lanepe.2022.100416","article-title":"Management of gout following 2016\/2017 European (EULAR) and British (BSR) guidelines: an interrupted time-series analysis in the United Kingdom","volume":"18","author":"Russell","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"2025030500184173000_keae229-B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2296-11-1","article-title":"Adaptation and validation of the Charlson Index for Read\/OXMIS coded databases","volume":"11","author":"Khan","year":"2010","journal-title":"BMC Fam Pract"},{"key":"2025030500184173000_keae229-B22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3899\/jrheum.140461","article-title":"Preventing attacks of acute gout when introducing urate-lowering therapy: a systematic literature review","volume":"92","author":"Seth","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"2025030500184173000_keae229-B23","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/acr.24357","article-title":"Cost-Effectiveness of colchicine prophylaxis for gout flares when commencing allopurinol","volume":"73","author":"Robinson","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025030500184173000_keae229-B24","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"2025030500184173000_keae229-B25","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"2025030500184173000_keae229-B26","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1161\/CIRCULATIONAHA.120.050771","article-title":"Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial","volume":"142","author":"Tong","year":"2020","journal-title":"Circulation"},{"key":"2025030500184173000_keae229-B27","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40264-020-00930-7","article-title":"Evidence of clinically meaningful drug\u2013drug interaction with concomitant use of colchicine and clarithromycin","volume":"43","author":"Villa Zapata","year":"2020","journal-title":"Drug Saf"},{"key":"2025030500184173000_keae229-B28","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1093\/eurheartj\/ehaa659","article-title":"Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)","volume":"41","author":"Bouabdallaoui","year":"2020","journal-title":"Eur Heart J"},{"key":"2025030500184173000_keae229-B29","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2025030500184173000_keae229-B30","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1016\/S2665-9913(23)00165-0","article-title":"Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomised trial","volume":"5","author":"Pascart","year":"2023","journal-title":"Lancet Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae229\/57421222\/keae229.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/3\/1147\/57421222\/keae229.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/3\/1147\/57421222\/keae229.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:21:36Z","timestamp":1741134096000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/3\/1147\/7651211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,4,18]]},"published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae229","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,4,18]]}}}